ABCSG 47 / IMpassion030 Summary
A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer
Start: | 07/2019 |
Coordinating Investigator: | Günther Steger, Vienna |
Sample size: | 2300 (international) |
Design: (Click to enlarge) |
![]() |